Theravance Biopharma Inc reports results for the quarter ended March 31 - Earnings Summary

Theravance Biopharma

08/05/2025 22:02

Theravance Biopharma Inc TBPH.OQ reported a quarterly adjusted loss of 27 cents​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of -24 cents.  The mean expectation of three analysts for the quarter was for a loss of 23 cents per share. Wall Street expected results to range from -24 cents to -22 cents per share.

Revenue rose 6.1% to $15.39 million from a year ago; analysts expected $15.50 million.

Theravance Biopharma Inc's reported EPS for the quarter was a loss of 27 cents​.

The company reported a quarterly loss of $13.58 million.

Theravance Biopharma Inc shares had risen by 11.9% this quarter and gained 6.2% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had fallen by about 3.6% in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Theravance Biopharma Inc is $13.50

This summary was machine generated from LSEG data May 8 at 09:00 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Mar. 31 2025
-0.23
-0.27
Missed
Dec. 31 2024
-0.21
-0.31
Missed
Sep. 30 2024
-0.23
-0.26
Missed
Jun. 30 2024
-0.21
-0.28
Missed